7th Apr 2016 06:27
LONDON (Alliance News) - Shire PLC reiterated its expectations that its acquisition of Chicago-based Baxalta Inc will proceed as it originally announced in January, as it acknowledged a notice from the US Treasure on Monday regarding new steps taken to curb so called 'tax inversions'.
The Dublin-based company expects the deal to be completed by mid-2016. The FTSE 100 pharmaceutical giant reiterated that the "combination of Shire and Baxalta is based on a strong strategic rationale to create the leading global biotechnology company focused on rare diseases."
The US Treasury on Monday outlined new steps to curb so called 'tax inversions', where US companies have looked to cut their tax rate by redomiciling overseas, and these new measures have already claimed their first casualty as Pfizer Inc terminated its USD10 billion merger with botox maker Allergan PLC on Wednesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire